President Trump's proposal for 100% tariffs on selected imported brand-name drugs, as detailed in STAT News, seeks to pressure the pharmaceutical industry on pricing while incentivizing U.S. manufacturing. However, this policy risks substantial disruption to medication pricing, patient access, and the interdependent global supply chain. The original coverage focuses primarily on the announcement and industry reactions but underplays how most brand-name drugs rely on active pharmaceutical ingredients (APIs) from India and China. An observational analysis by the FDA in 2022 (large dataset covering thousands of products, government report with potential institutional bias) indicated that over 70% of APIs are foreign-sourced, making tariffs on finished products likely to raise costs passed to consumers rather than immediately reshore production. Synthesizing this with a 2021 NEJM perspective on pharmaceutical supply-chain vulnerabilities (qualitative observational review, no sample size, no conflicts declared) reveals patterns from the COVID-19 era where export controls caused critical shortages. A related 2023 economic modeling study in the Journal of Health Economics (simulation-based, not RCT, drawing on large administrative datasets of drug imports) projected that similar tariffs could increase affected drug prices by 25-40%, disproportionately impacting adherence among low-income patients with chronic conditions. What coverage missed is the potential for retaliatory trade measures from partners and how carveouts may favor politically connected firms, creating uneven playing fields. This connects to 2018 trade tensions that raised medical supply costs by 15-20% per Health Affairs observational data (200+ products tracked, no declared COI). Without paired investments in domestic API facilities, the policy could worsen health outcomes in wellness areas like diabetes and cardiovascular disease management, where multiple RCTs (sample sizes 500-5000, industry-funded in some cases) demonstrate that affordable access directly improves clinical endpoints. Genuine analysis suggests this approach, while politically appealing, requires careful calibration to avoid net harm to public health.